Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04240886 · ClinicalTrials.gov registry record · Phase 2
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
A Phase 2 study, sponsored by Basilea Pharmaceutica.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04240886 is a Phase 2 study that was terminated before completion, run by Basilea Pharmaceutica. The registered enrollment target is 21 participants.
The verdict
NCT04240886, a Phase 2 study, was terminated before completion, sponsored by Basilea Pharmaceutica.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
Interventions
- DRUG fosmanogepix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-01-04 |
| Est. Completion | 2022-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04240886
The ClinicalTrials.gov registry entry for NCT04240886 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fosmanogepix is the first listed.
NCT04240886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04240886 about?
NCT04240886 is a clinical study titled "Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds". This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
What is the current status of trial NCT04240886?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2020-01-04. Estimated completion is 2022-05-09.
What interventions are being tested in trial NCT04240886?
The interventions under investigation include: fosmanogepix (DRUG).
Who is sponsoring clinical trial NCT04240886?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.